Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA Acquires Incyte Spin-off ProteoPlex; DNA Chip to Launch Soon

NEW YORK, Aug. 14 (GenomeWeb News) - A unit of Germany's Merck KGaA has acquired closely held ProteoPlex, a St. Louis-based proteomics company.


Terms of the deal, sealed on Aug. 7 and disclosed on Aug. 12, call for ProteoPlex to become integrated within the subsidiary, EMD Biosciences. The companies would not divulge the cost of the acquisition to Merck.


ProteoPlex, which was spun out from Incyte Genomics in 2001, manufactures DNA chips and protein chips. Its first product, a 16-well antibody array, will be launched with Merck's help.


"The technology and competence of ProteoPlex are a perfect fit with our own proteomics R&D programs and will directly translate into new product offerings for our customers in the Life Sciences industry," Bernd Reckman, vice president and general manager of Merck KGaA's Life Science Products Division, said in a statement.


ProteoPlex employs eight people and will remain in St. Louis, according to David Smoller, president and CEO.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.